Six key statistics on Conmed’s acquisition according the report:
1. Biomez is expected to increase Conmed’s gross margins, with an average margin of about 25 percent more in 2022.
2. Conmed stock’s price target has been lowered from $127 to $123.
3. Comed’s average debt following the acquisition is estimated to be five times its earnings or less.
4. Conmed expects the acquisition to add $1 million in revenue.
5. The deal is expected to be about 10 cents to 15 cents dilutive per share for both 2022 and 2023.
6. Conmed shares are up .74 percent to $98.29, as of Aug. 2.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
